| 2026-06-09 | 8-K | 10.1 | Consulting Services Agreement between the Registrant and Alethia Young |
|---|
| 2026-02-19 | 10-K | 10.47 | Amendment No. 2 to Amended and Restated Royalty Purchase Agreement and First Put Option Exercise Agreement, dated December 29, 2025, by and among PTC Therapeutics, Inc., Royalty Pharma Investments 2019 ICAV, and Royalty Pharma plc** |
|---|
| 2026-02-19 | 10-K | 10.42 | Amendment No. 6 to License Agreement dated October 24, 2025 by and between Shiratori Pharmaceutical Co. Ltd. and PTC Therapeutics MP, Inc.** |
|---|
| 2025-11-04 | 10-Q | 10.1 | Rights Satisfaction Agreement, dated August 5, 2025, by and among PTC Therapeutics, Inc., certain of the former securityholders of Censa Pharmaceuticals, Inc., and, for the limited purposes set forth in the agreement, Shareholder Representative Services LLC |
|---|
| 2025-02-27 | 10-K | 10.47 | License and Collaboration Agreement, dated as of November 27, 2024, among PTC Therapeutics, Inc., PTC Therapeutics HD, Inc. and Novartis Pharmaceuticals Corporation** |
|---|
| 2025-02-27 | 10-K | 10.46 | Asset Purchase Agreement, dated November 26, 2024, by and between the Buyer and PTC Therapeutics, Inc.** |
|---|
| 2025-02-27 | 10-K | 10.36 | Amendment, dated February 14, 2025, to Irrevocable Transferable Standby Letter of Credit, dated June 22, 2022, issued by HSBC Bank USA, N.A. in favor of Warren CC Acquisitions LLC c/o Vision Real Estate Partners for the Account of PTC Therapeutics, Inc.** |
|---|
| 2025-02-27 | 10-K | 10.34 | First Amendment to Lease Agreement, dated December 31, 2024, between Warren CC Acquisitions, LLC and PTC Therapeutics, Inc.** |
|---|
| 2024-08-08 | 10-Q | 10.2 | Amendment No. 1 to Amended and Restated Royalty Purchase Agreement and First Put Option Exercise Agreement, dated June 17, 2024, by and among PTC Therapeutics, Inc., Royalty Pharma Investments 2019 ICAV, and Royalty Pharma plc |
|---|
| 2024-08-08 | 10-Q | 10.1 | Amended and Restated Exclusive License and Supply Agreement, dated June 2, 2023, by and between PTC Therapeutics, Inc. and Faes Farma, S.A. |
|---|
| 2024-04-25 | 10-Q | 10.1 | Employment Agreement between PTC Therapeutics, Inc. and Lee Golden |
|---|
| 2024-02-29 | 10-K | 10.48 | Amended and Restated Royalty Purchase Agreement, dated as of October 18, 2023, among the Registrant, Royalty Pharma Investments 2019 ICAV, and solely for the purposes of Section 5.15 thereof, Royalty Pharma plc** |
|---|
| 2023-09-22 | 8-K | 10.1 | Credit Agreement dated as of October 27, 2022, among PTC Therapeutics, Inc., as the Borrower, each subsidiary of the Borrower from time to time party thereto, as Guarantors, the Lenders from time to time party thereto and Wilmington Trust, National Association, as Administrative Agent |
|---|
| 2023-08-03 | 10-Q | 10.1 | Amendment No. 5 to License Agreement dated April 28, 2023 by and between Shiratori Pharmaceutical Co. Ltd. and PTC Therapeutics MP, Inc. |
|---|
| 2023-07-17 | 8-K | 10.1 | Employment Agreement between PTC Therapeutics, Inc. and Pierre Gravier |
|---|
| 2023-04-27 | 10-Q | 10.2 | Funding Agreement, dated as of May 26, 2010, by and between the Registrant and The Wellcome Trust Limited |
|---|
| 2023-04-27 | 10-Q | 10.1 | Sponsored Research Agreement, as amended dated as of June 1, 2006, by and between the Registrant and Spinal Muscular Atrophy Foundation |
|---|
| 2023-04-18 | 8-K | 10.1 | Amended and Restated Employment Agreement between PTC Therapeutics, Inc. and Matthew Klein |
|---|
| 2023-03-24 | 8-K | 10.1 | Consulting Agreement between PTC Therapeutics, Inc. and Stuart W. Peltz |
|---|
| 2023-02-21 | 10-K | 10.56 | Stock Purchase Agreement, dated as of October 27, 2022 by and among the investors listed therein and PTC Therapeutics, Inc.** |
|---|
| 2023-02-21 | 10-K | 10.55 | Credit Agreement dated as of October 27, 2022, among PTC Therapeutics, Inc., as the Borrower, each subsidiary of the Borrower from time to time party thereto, as Guarantors, the Lenders from time to time party thereto and Wilmington Trust, National Association, as Administrative Agent** |
|---|
| 2023-02-21 | 10-K | 10.23 | Amendments to the Funding Agreement, dated as of May 26, 2010, by and between the Registrant and The Wellcome Trust Limited** |
|---|
| 2023-02-21 | 10-K | 10.21 | Form of Restricted Stock Unit Agreement under Amended and Restated 2013 Long Term Incentive Plan** |
|---|
| 2023-02-21 | 10-K | 10.20 | Form of Nonstatutory Stock Option Agreement under Amended and Restated 2013 Long Term Incentive Plan—Non-employee Director** |
|---|
| 2023-02-21 | 10-K | 10.19 | Form of Nonstatutory Stock Option Agreement under Amended and Restated 2013 Long Term Incentive Plan** |
|---|
| 2023-02-21 | 10-K | 10.18 | Form of Incentive Stock Option Agreement under Amended and Restated 2013 Long Term Incentive Plan** |
|---|
| 2022-12-06 | 8-K | 10.1 | Consulting Services Agreement between the Registrant and Dawn Svoronos |
|---|
| 2022-10-27 | 10-Q | 10.2 | Letter Agreement re: Collaboration and License Agreement, dated September 14, 2022, by and between Akcea Therapeutics, Inc. and PTC Therapeutics International Limited |
|---|
| 2022-10-27 | 10-Q | 10.1 | Letter Agreement re: Collaboration and License Agreement, dated July 25, 2022, by and between Akcea Therapeutics, Inc. and PTC Therapeutics International Limited |
|---|
| 2022-08-04 | 10-Q | 10.2 | Irrevocable Transferable Standby Letter of Credit, dated June 22, 2022, issued by HSBC Bank USA, N.A. in favor of Warren CC Acquisitions LLC c/o Vision Real Estate Partners for the Account of PTC Therapeutics, Inc. |
|---|
| 2022-08-04 | 10-Q | 10.1 | Lease Agreement dated May 24, 2022, between Warren CC Acquisitions, LLC and PTC Therapeutics, Inc. |
|---|
| 2022-06-09 | 8-K | 10.1 | PTC THERAPEUTICS, INC. AMENDED AND RESTATED 2013 LONG-TERM INCENTIVE PLAN |
|---|
| 2022-05-03 | 10-Q | 10.2 | Commercial Manufacturing Agreement, dated as of September 18, 2015, as amended, by and between Alcami Corporation (f/k/a/ AAI Pharma Services Corp.) and Complete Pharma Holdings, LLC (f/k/a Marathon Pharmaceuticals, LLC), as assigned by Complete Pharma Holdings, LLC to the Registrant on April 20, 2017 |
|---|
| 2022-05-03 | 10-Q | 10.1 | Collaborative Research Agreement Amendment 11, dated as of January 31, 2022 by and between National Taiwan University and PTC Therapeutics GT, Inc. |
|---|
| 2022-02-22 | 10-K | 10.53 | Collaborative Research Agreement Amendment 10, dated as of November 1, 2021 by and between National Taiwan University and PTC Therapeutics GT, Inc. |
|---|
| 2022-02-22 | 10-K | 10.44 | Employment Agreement, as amended, between the Registrant and Matthew Klein |
|---|
| 2021-06-09 | 8-K | 10.1 | PTC Therapeutics, Inc. Amended and Restated 2016 Employee Stock Purchase Plan |
|---|
| 2021-05-04 | 10-Q | 10.1 | Collaborative Research Agreement Amendment 9, dated as of March 21, 2021 by and between National Taiwan University and PTC Therapeutics GT, Inc. |
|---|
| 2021-02-25 | 10-K | 10.51 | Collaborative Research Agreement Amendment 8, dated as of December 5, 2020 by and between National Taiwan University and PTC Therapeutics GT, Inc. |
|---|
| 2021-02-25 | 10-K | 10.50 | Collaborative Research Agreement Amendment 7, dated as of September 14, 2020 by and between National Taiwan University and PTC Therapeutics GT, Inc. |
|---|
| 2020-10-29 | 10-Q | 10.2 | Collaborative Research Agreement Amendment 6, dated as of May 30, 2020 by and between National Taiwan University and PTC Therapeutics GT, Inc. |
|---|
| 2020-10-29 | 10-Q | 10.1 | Collaborative Research Agreement Amendment 5, dated as of January 17, 2020 by and between National Taiwan University and PTC Therapeutics GT, Inc. |
|---|
| 2020-08-05 | 10-Q | 10.4 | EX-10.4 PAUWELS EMPLOYMENT AGREEMENT |
|---|
| 2020-08-05 | 10-Q | 10.3 | EX-10.3 KLEIN EMPLOYMENT AGREEMENT |
|---|
| 2020-08-05 | 10-Q | 10.2 | EX-10.2 RPI ROYALTY PURCHASE AGREEMENT |
|---|
| 2020-08-05 | 10-Q | 10.1 | EX-10.1 SHIRATORI LICENSE AGREEMENT |
|---|
| 2020-04-30 | 10-Q | 10.1 | Second Amendment to Lease Agreement dated as of March 25, 2020 by and between Bristol-Myers Squibb Company and PTC Therapeutics, Inc. |
|---|
| 2020-04-30 | 8-K | 10.1 | Rights Exchange Agreement, by and among PTC Therapeutics, Inc., the Rightholders set forth therein, and, for the limited purposes set forth therein, Shareholder Representative Services LLC, dated as of April 29, 2020 |
|---|
| 2020-03-02 | 10-K | 10.51 | First Amendment to Lease Agreement dated as of October 7, 2019 by and between Bristol-Myers Squibb Company and PTC Therapeutics, Inc. |
|---|
| 2020-03-02 | 10-K | 10.42 | License and Technology Transfer Agreement Amendment No. 2, dated December 1, 2019, by and among National Taiwan University, Professor Wu-Lian (Paul) Hwu and PTC Therapeutics GT, Inc. |
|---|
| 2019-10-30 | 10-Q | 10.6 | Irrevocable Standby Letter of Credit, dated September 3, 2019, issued by HSBC Bank USA, N.A. in favor of Bristol-Myers Squibb Company for the Account of PTC Therapeutics, Inc., as amended |
|---|
| 2019-10-30 | 10-Q | 10.5 | Lease Agreement dated as of August 3, 2019, by and between Bristol-Myers Squibb Company and PTC Therapeutics, Inc. |
|---|
| 2019-10-30 | 10-Q | 10.4 | Omnibus Amendment No. 5 and Joinder to Credit and Security Agreement and Amendment and Joinder to Pledge Agreement, dated as of October 1, 2019, by and among PTC Therapeutics, Inc., each of the subsidiaries listed therein as a New Borrower, MidCap Financial Trust and the Lenders as defined therein |
|---|
| 2019-10-30 | 10-Q | 10.3 | Amendment No. 4 to Credit and Security Agreement, dated as of September 17, 2019, by and among PTC Therapeutics, Inc., MidCap Financial Trust and the Lenders as defined therein |
|---|
| 2019-10-30 | 10-Q | 10.2 | Amendment No. 3 to Credit and Security Agreement, dated as of August 29, 2019, by and among PTC Therapeutics, Inc., MidCap Financial Trust and the Lenders as defined therein |
|---|
| 2019-10-30 | 10-Q | 10.1 | Amendment No. 2 to Credit and Security Agreement, dated as of August 7, 2019, by and among PTC Therapeutics, Inc., MidCap Financial Trust and the Lenders as defined therein |
|---|
| 2019-08-06 | 10-Q | 10.2 | Employment Agreement, as amended, between the Registrant and Christine Utter |
|---|
| 2019-08-06 | 10-Q | 10.1 | Employment Agreement, as amended, between the Registrant and Emily Hill |
|---|
| 2018-11-05 | 10-Q | 10.5 | Collaboration and License Agreement, dated August 1, 2018, by and between PTC Therapeutics International Limited and Akcea Therapeutics, Inc. |
|---|
| 2018-11-05 | 10-Q | 10.4 | License and Technolgy Transfer Agreement, dated December 23, 2015, by and between National Taiwan University and Agilis Biotherapeutics, Inc. (formerly Agilis Biotherapeutics, LLC) |
|---|
| 2018-11-05 | 10-Q | 10.3 | Collaborative Research Agreement, dated September 30, 2015, as amended, by and between National Taiwan University and Agilis Biotherapeutics, Inc. (formerly Agilis Biotherapeutics, LLC) |
|---|
| 2018-07-19 | 8-K | 10.2 | Amendment No. 1 and Limited Consent to Credit and Security Agreement, dated of as July 19, 2018, by and among PTC Therapeutics, Inc., MidCap Financial Trust, and the Lenders as defined therein |
|---|
| 2018-07-19 | 8-K | 10.1 | Bridge Loan and Security Agreement, dated as of July 19, 2018, by and among PTC Therapeutics, Inc., Agilis Biotherapeutics, Inc., and the Guarantors as defined therein |
|---|
| 2017-09-18 | 8-K | 10.1 | Consulting Services Agreement between the Registrant and Dr. C. Geoffrey McDonough |
|---|
| 2017-08-09 | 10-Q | 10.7 | Employment Agreement, as amended, between the Registrant and Christine Utter |
|---|
| 2017-08-09 | 10-Q | 10.6 | Employment Agreement, as amended, between the Registrant and Marcio Souza |
|---|
| 2017-08-09 | 10-Q | 10.2 | Commercial Manufacturing Agreement, dated as of September 18, 2015, as amended, by and between Alcami Corporation (f/k/a/ AAI Pharma Services Corp.) and Complete Pharma Holdings, LLC (f/k/a Marathon Pharmaceuticals, LLC), as assigned by Complete Pharma Holdings, LLC to the Registrant on April 20, 2017 |
|---|
| 2017-08-09 | 10-Q | 10.1 | Exclusive License and Supply Agreement, dated as of May 12, 2015, as amended, by and between Faes Farma, S.A. and Complete Pharma Holdings, LLC (f/k/a Marathon Pharmaceuticals, LLC), as assigned by Complete Pharma Holdings, LLC to the Registrant on April 20, 2017 |
|---|
| 2017-08-08 | 8-K | 10.1 | Consulting Services Agreement between the Registrant and Mark A. Rothera |
|---|
| 2017-05-08 | 8-K | 10.3 | Intellectual Property Security Agreement, dated May 5, 2017, by and among PTC Therapeutics Inc. and MidCap Financial Trust. |
|---|
| 2017-05-08 | 8-K | 10.2 | Pledge Agreement, dated May 5, 2017, by and among PTC Therapeutics Inc., each of the subsidiaries listed thereto as pledgers and MidCap Financial Trust. |
|---|
| 2017-05-08 | 8-K | 10.1 | Credit and Security Agreement, dated May 5, 2017, by and among PTC Therapeutics Inc., MidCap Financial Trust and the additional lenders thereto. |
|---|
| 2017-03-16 | 10-K | 10.19 | Form of Restricted Stock Agreement under 2013 Long Term Incentive Plan —2017 |
|---|
| 2016-04-27 | 8-K | 10.1 | Consulting Services Agreement |
|---|
| 2016-02-29 | 10-K | 10.32 | PTC THERAPEUTICS, INC. RESTRICTED STOCK UNIT AGREEMENT |
|---|
| 2016-02-29 | 10-K | 10.31 | Nonstatutory Stock Option Agreement |
|---|
| 2015-03-02 | 10-K | 10.26 | SEPARATION AND GENERAL RELEASE AGREEMENT |
|---|
| 2015-03-02 | 10-K | 10.16 | Nonstatutory Stock Option Agreement |
|---|
| 2015-03-02 | 10-K | 10.15 | Incentive Stock Option Agreement |
|---|
| 2015-03-02 | 10-K | 10.14 | Nonstatutory Stock Option Agreement |
|---|
| 2014-05-06 | 10-Q | 10.2 | Employment Agreement between the Registrant and Robert J. Spiegel |
|---|